HopeStage
Back to all studies
CompletedNCT00386581

Atomoxetine for ADHD in children and adolescents in Russia

About this titleRead the official source — NCT00386581

This study evaluated the safety and effectiveness of atomoxetine for people with ADHD.

Medication studyAges 6–16Russia
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of atomoxetine for people with ADHD.

Who was this study for?

Listed age limits: 6 years to 16 years.

Listed locations
MoscowSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2004
Recruitment status
Completed
Enrollment listed in the registry
105
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Russia
Age range
From 6 Years to 16 Years
Official registry ID
NCT00386581
Official title
Show the full official title

Phase III Multicenter, Randomized, Double-Blind Placebo-Controlled Outpatient Study of Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Moscow, Russia · Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of atomoxetine for people with ADHD.

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including atomoxetine and placebo.

Who was this study for?

Listed age limits: 6 years to 16 years.

Want to explore more studies?

Explore studies